Central Nervous System Therapeutics Global Market Report 2026
상품코드:1951598
리서치사:The Business Research Company
발행일:On Demand Report
페이지 정보:영문 250 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
중추신경계 치료제 시장 규모는 최근 현저한 성장을 이루고 있습니다. 2025년 1,349억 9,000만 달러에서 2026년에는 1,472억 9,000만 달러로, CAGR 9.1%로 확대될 것으로 예상됩니다. 지난 수년간의 성장은 우울증과 간질 부담 증가, 고령화 인구 증가, 퇴행성 질환에 대한 치료 옵션의 제한, 중추신경계 질환 입원율 증가, 병원 및 진료소 인프라 확충 등이 원인으로 추정됩니다.
중추신경계 치료제 시장 규모는 향후 몇 년간 강력한 성장이 전망됩니다. 2030년에는 2,066억 8,000만 달러에 달하고, CAGR은 8.8%가 될 전망입니다. 예측 기간 동안의 성장 요인으로는 신규 신경보호제 개발, 생물학적 제제 및 유전자 치료 확대, 신경과학 연구 투자 증가, 맞춤형 의료 도입 확대, 신흥 시장에서의 중추신경계 치료 접근성 확대 등을 꼽을 수 있습니다. 예측 기간의 주요 동향으로는 신경 및 정신질환 유병률 증가, 중추신경계 질환에 대한 병용요법의 보급 확대, 장기적인 질환 관리 및 증상 조절에 대한 관심 증가, 홈케어형 중추신경계 치료 솔루션의 확대, 혈액뇌관문 투과성을 개선한 약물 제제 개발 등을 들 수 있습니다.
정신질환의 유병률 증가는 향후 몇 년간 중추신경계(CNS) 치료제 시장의 성장을 견인할 것으로 예상됩니다. 정신질환이란 우울증, 불안장애, 정신분열증, 조울증, 양극성 장애 등 사람의 사고, 감정, 행동, 기분에 영향을 미치는 광범위한 상태를 말합니다. 이러한 질병의 증가 추세는 주로 만성 스트레스에 대한 노출 증가에 기인하는 것으로 여겨집니다. 만성적인 스트레스는 감정 조절 기능을 방해하고 대처 능력을 약화시켜 불안, 우울증, 번아웃 등의 증상을 유발할 수 있습니다. 중추신경계 치료제는 기분, 행동, 인지 등을 조절하는 뇌 내 화학제품과 신경 경로를 표적으로 삼아 정신질환을 치료합니다. 예를 들어, 영국 지방정부인 브리스톨 시의회가 발표한 보고서에 따르면, 2025년 12월 기준 2022-23년도에 브리스톨 시내 GP 진료소의 우울증 등록 환자 수는 18세 이상 66,815명으로 기록되어 2021-22년도에 비해 6.0% 증가한 것으로 나타났습니다. 따라서 정신질환 유병률의 증가는 중추신경계 치료제 시장의 성장을 견인하고 있습니다.
중추신경계 치료제 시장에서 사업을 전개하는 주요 기업들은 신경질환 치료에서 표적 유전자 전달 강화, 치료 효과 향상, 혈액뇌관문 투과성 최적화, 캡슐화 엔지니어링 등 혁신적인 솔루션에 집중하고 있습니다. 캡시드 엔지니어링은 유전자 치료에 사용되는 바이러스 벡터(주로 아데노 부속 바이러스 : AAV)의 단백질 껍질(캡시드)을 변형-최적화하는 기술입니다. 예를 들어, 2025년 5월 프랑스에 본사를 둔 생명공학 기업 Coave Therapeutics S.A.(Coave Therapeutics S.A.)는 자체 개발한 ALIGATER 플랫폼을 이용한 중추신경계 전달을 위한 신규 AAV 'coAAV CSF-01'을 발표했습니다. 이 벡터는 AAV9에 비해 트랜스듀션 효율과 안전성이 현저하게 향상된 것으로 입증되었습니다. 뇌실내 대뇌척수액강 내 및 뇌실 경로로 투여된 coAAV-CSF-01은 같은 용량에서 대뇌피질에서 100배, 해마에서 10,000배 더 높은 트랜스진 발현을 달성했습니다. AAV9의 5분의 1의 용량으로 AAV9과 동등한 발현 수준을 달성하여 우수한 효능을 보여주었습니다. 또한, 간 등 말초 장기에서 표적 외 발현이 현저히 감소하고, 말초신경 건강 유지 등 우수한 안전성 프로파일을 유지함. 이를 통해 보다 높은 정확도와 낮은 전신 위험으로 중추신경계 유전자 치료의 결과를 개선할 수 있는 가능성을 보여주었습니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 공급망 분석
제4장 세계 시장 동향과 전략
제5장 최종 이용 산업 시장 분석
제6장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세의 영향, 관세 전쟁과 무역 보호주의가 공급망에 미치는 영향, 코로나가 시장에 미치는 영향을 포함한 거시경제 시나리오
제7장 세계의 전략 분석 프레임워크, 현재 시장 규모, 시장 비교 및 성장률 분석
제8장 시장에서 세계의 총 잠재 시장 규모(TAM)
제9장 시장 세분화
제10장 지역별, 국가별 분석
제11장 아시아태평양 시장
제12장 중국 시장
제13장 인도 시장
제14장 일본 시장
제15장 호주 시장
제16장 인도네시아 시장
제17장 한국 시장
제18장 대만 시장
제19장 동남아시아 시장
제20장 서유럽 시장
제21장 영국 시장
제22장 독일 시장
제23장 프랑스 시장
제24장 이탈리아 시장
제25장 스페인 시장
제26장 동유럽 시장
제27장 러시아 시장
제28장 북미 시장
제29장 미국 시장
제30장 캐나다 시장
제31장 남미 시장
제32장 브라질 시장
제33장 중동 시장
제34장 아프리카 시장
제35장 시장 규제 상황과 투자 환경
제36장 경쟁 구도와 기업 개요
제37장 기타 주요 기업과 혁신적 기업
제38장 세계의 시장 경쟁 벤치마킹과 대시보드
제39장 주요 인수합병
제40장 시장 잠재력이 높은 국가, 부문, 전략
제41장 부록
KSM
영문 목차
영문목차
Central nervous system therapeutics are drugs and treatment approaches developed to manage and treat disorders of the brain and spinal cord. These include conditions such as depression, epilepsy, Parkinson's disease, and multiple sclerosis. Their purpose is to restore neurological function, relieve symptoms, and improve patients' quality of life. They encompass pharmaceuticals, biologics, and advanced neurotechnological interventions.
The main drug classes in central nervous system therapeutics include anesthetics, anticonvulsants, antiemetics, central nervous system (CNS) stimulants, pain relievers, and others. Anesthetics are medications that block pain or induce unconsciousness during medical procedures. These therapies are applied across various disease areas, including neurovascular disorders, mental health conditions, degenerative diseases, genetic disorders, substance abuse, autoimmune and inflammatory diseases, CNS trauma, infectious diseases, CNS cancers, and others. They are distributed through channels such as hospital pharmacies, retail pharmacies, and others, and are used in applications including hospitals, clinics, homecare, and other care settings.
Tariffs have impacted the central nervous system therapeutics market by increasing the cost of imported active pharmaceutical ingredients, biologics, and specialized manufacturing equipment, leading to higher production expenses and pricing pressures. Drug classes such as biologics and advanced neurotherapies are most affected, particularly in regions like North America and Europe that depend on global supply chains. These challenges have caused temporary delays in product availability. However, tariffs have also encouraged domestic manufacturing, regional supply chain diversification, and increased investment in local R&D for CNS therapeutics.
The central nervous system therapeutics market research report is one of a series of new reports from The Business Research Company that provides central nervous system therapeutics market statistics, including central nervous system therapeutics industry global market size, regional shares, competitors with a central nervous system therapeutics market share, detailed central nervous system therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the central nervous system therapeutics industry. This central nervous system therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The central nervous system therapeutics market size has grown strongly in recent years. It will grow from $134.99 billion in 2025 to $147.29 billion in 2026 at a compound annual growth rate (CAGR) of 9.1%. The growth in the historic period can be attributed to increasing burden of depression and epilepsy, growing aging population, limited treatment options for degenerative disorders, rising hospitalization rates for cns conditions, expansion of hospital and clinic infrastructure.
The central nervous system therapeutics market size is expected to see strong growth in the next few years. It will grow to $206.68 billion in 2030 at a compound annual growth rate (CAGR) of 8.8%. The growth in the forecast period can be attributed to development of novel neuroprotective agents, growth in biologics and gene-based therapies, increasing investment in neuroscience research, rising adoption of personalized medicine, expanding access to cns treatments in emerging markets. Major trends in the forecast period include rising prevalence of neurological and mental health disorders, growing adoption of combination therapies for cns diseases, increasing focus on long-term disease management and symptom control, expansion of homecare-based cns treatment solutions, improved drug formulations with better blood-brain barrier penetration.
The increasing prevalence of mental health disorders is expected to drive the growth of the central nervous system (CNS) therapeutics market in the coming years. Mental health disorders encompass a broad range of conditions that affect a person's thinking, emotions, behavior, or mood, including depression, anxiety disorders, schizophrenia, and bipolar disorder. The rising prevalence of these disorders is largely attributed to greater exposure to chronic stress, which can disrupt emotional regulation, weaken coping mechanisms, and contribute to conditions such as anxiety, depression, and burnout. CNS therapeutics address mental health disorders by targeting brain chemicals and neural pathways that regulate mood, behavior, and cognition. For instance, in December 2025, according to a report published by Bristol City Council, a UK-based local government authority, 66,815 patients aged 18 and above were recorded on GP practice depression registers in Bristol during 2022-23, representing a 6.0% increase from 2021-22. Therefore, the rising prevalence of mental health disorders is driving the growth of the CNS therapeutics market.
Major companies operating in the CNS therapeutics market are focusing on innovative solutions such as capsid engineering to enhance targeted gene delivery, improve therapeutic efficacy, and optimize blood-brain barrier penetration for neurological disorder treatments. Capsid engineering involves modifying and optimizing the protein shell (capsid) of viral vectors, typically adeno-associated viruses (AAVs), used in gene therapy. For example, in May 2025, Coave Therapeutics S.A., a France-based biotechnology company, launched coAAV CSF-01, a novel AAV for CNS delivery using their proprietary ALIGATER platform. The vector demonstrated significantly enhanced transduction efficiency and safety compared to AAV9. Delivered via intracisternal magna and intracerebroventricular routes, coAAV-CSF-01 achieved 100-fold higher transgene expression in the cortex and 10,000-fold higher expression in the hippocampus at the same dose. Equivalent expression levels to AAV9 were achieved at just one-fifth of the dose, highlighting its superior potency. The vector also showed markedly reduced off-target expression in peripheral organs such as the liver while maintaining a favorable safety profile, including preserved peripheral nerve integrity, underscoring its potential to improve CNS gene therapy outcomes with higher precision and lower systemic risk.
In June 2025, Supernus Pharmaceuticals Inc., a US-based biopharmaceutical company, acquired Sage Therapeutics Inc. for an undisclosed amount. This acquisition allows Supernus to expand its neuroscience portfolio, strengthen its position in the CNS market, and accelerate the development of innovative treatments for depression and other mood disorders. Sage Therapeutics Inc. is a US-based biopharmaceutical company specializing in CNS therapeutics.
Major companies operating in the central nervous system therapeutics market are Biogen Inc., Otsuka Pharmaceutical Co Ltd., UCB S.A., Jazz Pharmaceuticals plc, Supernus Pharmaceuticals Inc., Biohaven Ltd., Acadia Pharmaceuticals Inc., Neumora Therapeutics Inc., Cerevel Therapeutics LLC, Axsome Therapeutics Inc., TauRx Therapeutics Ltd., Autobahn Therapeutics, BrainStorm Cell Therapeutics Inc., Progentos Therapeutics Inc., Tonix Pharmaceuticals Holding Corp., Neuroplast B.V., Assertio Holdings Inc.
North America was the largest region in the central nervous system therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the central nervous system therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the central nervous system therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The central nervous system therapeutics market consists of sales of sodium channel blockers, amphetamines, and neuroprotective agents. Values in this market are 'factory gate' values; that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Central Nervous System Therapeutics Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses central nervous system therapeutics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on end user analysis.
Benchmark performance against key competitors based on market share, innovation, and brand strength.
Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for central nervous system therapeutics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The central nervous system therapeutics market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Scope
Markets Covered:1) By Drug Class: Anesthetics; Anticonvulsants; Antiemetics; Central Nervous System (CNS) Stimulants; Pain Relievers; Other Drug Classes
2) By Disease: Neurovascular Diseases; Mental Health; Degenerative Disorders; Genetic Diseases; Substance Abuse Disorders; Autoimmune And Inflammatory Diseases; Central Nervous System (CNS) Trauma; Infectious Diseases; Central Nervous System (CNS) Cancer; Other Diseases
3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Other Distribution Channels
4) By Application: Hospital; Clinic; Homecare; Other Applications
Subsegments:
1) By Anesthetics: General Anesthetics; Local Anesthetics; Dissociative Anesthetics; Inhalation Anesthetics; Intravenous Anesthetics
4) By Central Nervous System (CNS) Stimulants: Amphetamines; Methylphenidates; Modafinil and Armodafinil; Caffeine-Based Stimulants; Xanthine Derivatives
5) By Pain Relievers: Opioid Analgesics; Antidepressants for Neuropathic Pain; Anticonvulsants for Pain Relief
6) By Other Drug Classes: Antipsychotics; Antidepressants; Muscle Relaxants; Sedatives and Hypnotics; Neuroprotective Agents
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report
+ Excel Dashboard
Added Benefits
Bi-Annual Data Update
Customisation
Expert Consultant Support
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.
4.1.3 Digitalization, Cloud, Big Data & Cybersecurity
4.1.4 Internet Of Things (Iot), Smart Infrastructure & Connected Ecosystems
4.1.5 Industry 4.0 & Intelligent Manufacturing
4.2. Major Trends
4.2.1 Rising Prevalence Of Neurological And Mental Health Disorders
4.2.2 Growing Adoption Of Combination Therapies For Cns Diseases
4.2.3 Increasing Focus On Long-Term Disease Management And Symptom Control
4.2.4 Expansion Of Homecare-Based Cns Treatment Solutions
4.2.5 Improved Drug Formulations With Better Blood-Brain Barrier Penetration
5. Central Nervous System Therapeutics Market Analysis Of End Use Industries
5.1 Hospitals
5.2 Clinics
5.3 Homecare Settings
5.4 Specialty Neurology Centers
5.5 Rehabilitation And Long-Term Care Centers
6. Central Nervous System Therapeutics Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market
7. Global Central Nervous System Therapeutics Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis
7.1. Global Central Nervous System Therapeutics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
7.2. Global Central Nervous System Therapeutics Market Size, Comparisons And Growth Rate Analysis
7.3. Global Central Nervous System Therapeutics Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
7.4. Global Central Nervous System Therapeutics Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)
8. Global Central Nervous System Therapeutics Total Addressable Market (TAM) Analysis for the Market
8.1. Definition and Scope of Total Addressable Market (TAM)
8.2. Methodology and Assumptions
8.3. Global Total Addressable Market (TAM) Estimation
8.4. TAM vs. Current Market Size Analysis
8.5. Strategic Insights and Growth Opportunities from TAM Analysis
9. Central Nervous System Therapeutics Market Segmentation
9.1. Global Central Nervous System Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Anesthetics, Anticonvulsants, Antiemetics, Central Nervous System (CNS) Stimulants, Pain Relievers, Other Drug Classes
9.2. Global Central Nervous System Therapeutics Market, Segmentation By Disease, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Neurovascular Diseases, Mental Health, Degenerative Disorders, Genetic Diseases, Substance Abuse Disorders, Autoimmune And Inflammatory Diseases, Central Nervous System (CNS) Trauma, Infectious Diseases, Central Nervous System (CNS) Cancer, Other Diseases
9.3. Global Central Nervous System Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Hospital Pharmacies, Retail Pharmacies, Other Distribution Channels
9.4. Global Central Nervous System Therapeutics Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Hospital, Clinic, Homecare, Other Applications
9.5. Global Central Nervous System Therapeutics Market, Sub-Segmentation Of Anesthetics, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
General Anesthetics, Local Anesthetics, Dissociative Anesthetics, Inhalation Anesthetics, Intravenous Anesthetics
9.6. Global Central Nervous System Therapeutics Market, Sub-Segmentation Of Anticonvulsants, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
9.7. Global Central Nervous System Therapeutics Market, Sub-Segmentation Of Antiemetics, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
9.8. Global Central Nervous System Therapeutics Market, Sub-Segmentation Of Central Nervous System (CNS) Stimulants, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Amphetamines, Methylphenidates, Modafinil and Armodafinil, Caffeine-Based Stimulants, Xanthine Derivatives
9.9. Global Central Nervous System Therapeutics Market, Sub-Segmentation Of Pain Relievers, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Opioid Analgesics, Antidepressants for Neuropathic Pain, Anticonvulsants for Pain Relief
9.10. Global Central Nervous System Therapeutics Market, Sub-Segmentation Of Other Drug Classes, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Antipsychotics, Antidepressants, Muscle Relaxants, Sedatives and Hypnotics, Neuroprotective Agents
10. Central Nervous System Therapeutics Market Regional And Country Analysis
10.1. Global Central Nervous System Therapeutics Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
10.2. Global Central Nervous System Therapeutics Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
11. Asia-Pacific Central Nervous System Therapeutics Market
11.1. Asia-Pacific Central Nervous System Therapeutics Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
11.2. Asia-Pacific Central Nervous System Therapeutics Market, Segmentation By Drug Class, Segmentation By Disease, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
12. China Central Nervous System Therapeutics Market
12.1. China Central Nervous System Therapeutics Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
12.2. China Central Nervous System Therapeutics Market, Segmentation By Drug Class, Segmentation By Disease, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
13. India Central Nervous System Therapeutics Market
13.1. India Central Nervous System Therapeutics Market, Segmentation By Drug Class, Segmentation By Disease, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
14. Japan Central Nervous System Therapeutics Market
14.1. Japan Central Nervous System Therapeutics Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
14.2. Japan Central Nervous System Therapeutics Market, Segmentation By Drug Class, Segmentation By Disease, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
15. Australia Central Nervous System Therapeutics Market
15.1. Australia Central Nervous System Therapeutics Market, Segmentation By Drug Class, Segmentation By Disease, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
16. Indonesia Central Nervous System Therapeutics Market
16.1. Indonesia Central Nervous System Therapeutics Market, Segmentation By Drug Class, Segmentation By Disease, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
17. South Korea Central Nervous System Therapeutics Market
17.1. South Korea Central Nervous System Therapeutics Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
17.2. South Korea Central Nervous System Therapeutics Market, Segmentation By Drug Class, Segmentation By Disease, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
18. Taiwan Central Nervous System Therapeutics Market
18.1. Taiwan Central Nervous System Therapeutics Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
18.2. Taiwan Central Nervous System Therapeutics Market, Segmentation By Drug Class, Segmentation By Disease, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
19. South East Asia Central Nervous System Therapeutics Market
19.1. South East Asia Central Nervous System Therapeutics Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
19.2. South East Asia Central Nervous System Therapeutics Market, Segmentation By Drug Class, Segmentation By Disease, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
20. Western Europe Central Nervous System Therapeutics Market
20.1. Western Europe Central Nervous System Therapeutics Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
20.2. Western Europe Central Nervous System Therapeutics Market, Segmentation By Drug Class, Segmentation By Disease, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
21. UK Central Nervous System Therapeutics Market
21.1. UK Central Nervous System Therapeutics Market, Segmentation By Drug Class, Segmentation By Disease, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
22. Germany Central Nervous System Therapeutics Market
22.1. Germany Central Nervous System Therapeutics Market, Segmentation By Drug Class, Segmentation By Disease, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
23. France Central Nervous System Therapeutics Market
23.1. France Central Nervous System Therapeutics Market, Segmentation By Drug Class, Segmentation By Disease, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
24. Italy Central Nervous System Therapeutics Market
24.1. Italy Central Nervous System Therapeutics Market, Segmentation By Drug Class, Segmentation By Disease, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
25. Spain Central Nervous System Therapeutics Market
25.1. Spain Central Nervous System Therapeutics Market, Segmentation By Drug Class, Segmentation By Disease, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
26. Eastern Europe Central Nervous System Therapeutics Market
26.1. Eastern Europe Central Nervous System Therapeutics Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
26.2. Eastern Europe Central Nervous System Therapeutics Market, Segmentation By Drug Class, Segmentation By Disease, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
27. Russia Central Nervous System Therapeutics Market
27.1. Russia Central Nervous System Therapeutics Market, Segmentation By Drug Class, Segmentation By Disease, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
28. North America Central Nervous System Therapeutics Market
28.1. North America Central Nervous System Therapeutics Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
28.2. North America Central Nervous System Therapeutics Market, Segmentation By Drug Class, Segmentation By Disease, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
29. USA Central Nervous System Therapeutics Market
29.1. USA Central Nervous System Therapeutics Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
29.2. USA Central Nervous System Therapeutics Market, Segmentation By Drug Class, Segmentation By Disease, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
30. Canada Central Nervous System Therapeutics Market
30.1. Canada Central Nervous System Therapeutics Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
30.2. Canada Central Nervous System Therapeutics Market, Segmentation By Drug Class, Segmentation By Disease, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
31. South America Central Nervous System Therapeutics Market
31.1. South America Central Nervous System Therapeutics Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
31.2. South America Central Nervous System Therapeutics Market, Segmentation By Drug Class, Segmentation By Disease, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
32. Brazil Central Nervous System Therapeutics Market
32.1. Brazil Central Nervous System Therapeutics Market, Segmentation By Drug Class, Segmentation By Disease, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
33. Middle East Central Nervous System Therapeutics Market
33.1. Middle East Central Nervous System Therapeutics Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
33.2. Middle East Central Nervous System Therapeutics Market, Segmentation By Drug Class, Segmentation By Disease, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
34. Africa Central Nervous System Therapeutics Market
34.1. Africa Central Nervous System Therapeutics Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
34.2. Africa Central Nervous System Therapeutics Market, Segmentation By Drug Class, Segmentation By Disease, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
35. Central Nervous System Therapeutics Market Regulatory and Investment Landscape
36. Central Nervous System Therapeutics Market Competitive Landscape And Company Profiles
36.1. Central Nervous System Therapeutics Market Competitive Landscape And Market Share 2024
36.1.1. Top 10 Companies (Ranked by revenue/share)
36.2. Central Nervous System Therapeutics Market - Company Scoring Matrix
36.2.1. Market Revenues
36.2.2. Product Innovation Score
36.2.3. Brand Recognition
36.3. Central Nervous System Therapeutics Market Company Profiles
36.3.1. Biogen Inc. Overview, Products and Services, Strategy and Financial Analysis
36.3.2. Otsuka Pharmaceutical Co Ltd. Overview, Products and Services, Strategy and Financial Analysis
36.3.3. UCB S.A. Overview, Products and Services, Strategy and Financial Analysis
36.3.4. Jazz Pharmaceuticals plc Overview, Products and Services, Strategy and Financial Analysis
36.3.5. Supernus Pharmaceuticals Inc. Overview, Products and Services, Strategy and Financial Analysis
37. Central Nervous System Therapeutics Market Other Major And Innovative Companies
